Tumor Inhibition
Tumor Inhibition - Related Videos
01:18
Thermally Responsive Biopolymer-Based Inhibition of Tumor Progression in a Rat Model
0 Views •
2025
Begin with an anesthetized rat bearing a brain tumor composed of proliferating tumor cells.Expose the rat’s skull and create a hole to reveal the brain region with the tumor.Take a thermally responsive biopolymer fused with a cell-penetrating peptide and an inhibitor of c-myc, an oncogenic protein.Inject the biopolymer into the femoral vein of the hind limb for delivery to the brain.Apply infrared light through the skull hole to heat the tumor site, which induces biopolymer aggregation along...
00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
0 Views •
2019
This protocol describes xenograft and orthotopic mouse models of human thyroid tumorigenesis as a platform to test microRNA-based inhibitor treatments. This approach is ideal to study the function of non-coding RNAs and their potential as new therapeutic targets.
00:46
Feedback Inhibition
0 Views •
2019
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell! Since enzymes help control the rate of reactions, their activity is regulated so that appropriate amounts of starting materials, intermediate metabolites, and products are maintained in the cell. Excessive build-up or depletion of...
01:29
Anti-Tumor Effects of Engineered Pediococcus pentosaceus in a Mouse Tumor Model
0 Views •
2026
Begin with immunodeficient mice bearing subcutaneous xenograft tumors derived from human colorectal cancer cells.Orally administer Pediococcus pentosaceus, a lactic acid bacterium safe for consumption and engineered to secrete an anticancer protein, to the treated mouse.Administer saline to the control mouse.Being acid-tolerant, the bacteria survive the acidic environment of the stomach and reach the intestine.There, they colonize the intestinal lumen and secrete the anticancer protein.The...
01:30
Enzyme Inhibition
0 Views •
2025
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure. Competitive inhibitors occupy the active site of enzymes, making them unable to accommodate the substrate. However, sufficiently high...
FAQs
At the cellular level, treatment can interrupt progression through the cell cycle, preventing malignant cells from continuing to divide. It may also activate apoptosis, a regulated form of cell death, reducing the survival of abnormal cells. These mechanisms provide distinct ways to lower cellular activity and can be examined when evaluating whether a therapy is suppressing tumor growth.
Restricting blood-vessel formation can limit the support available to a growing tumor, while improving immune recognition can help immune cells identify and eliminate malignant cells. These mechanisms address different requirements for tumor persistence. Their inclusion in treatment research broadens evaluation beyond direct effects on cancer-cell division and helps explain how therapies may produce inhibition through complementary biological routes.
Chemotherapy, targeted therapy, immunotherapy, and radiation can be studied as separate approaches because they may interrupt tumor progression through different mechanisms. Immunotherapy emphasizes recognition and elimination by immune cells, whereas other treatments may affect cellular activity more directly. Comparing these approaches helps researchers identify which biological process is being influenced and supports consideration of combination treatments.
The observed level can vary according to how strongly treatment affects cell-cycle progression, apoptosis, blood-vessel formation, immune recognition, or malignant spread. Resistance is another important consideration because it can reduce treatment effectiveness. Researchers therefore examine several indicators, including tumor size, cellular activity, biomarkers, and metastatic potential, rather than relying on a single measurement.
Evaluation commonly combines changes in tumor size with measures of cellular activity, biomarkers, and metastatic potential. These indicators provide complementary information: size reflects a visible tumor change, while cellular and molecular measures can reveal biological effects during treatment. Using multiple outcomes helps researchers assess the response to chemotherapy, targeted therapy, immunotherapy, radiation, or combinations.
Tumor inhibition provides a framework for drug development and treatment selection. Researchers can use response measurements to study whether a candidate therapy affects malignant tissue and to compare treatment approaches. Clinicians and investigators also consider the balance between suppressing cancer and limiting damage to healthy tissue, making the concept relevant to both therapeutic research and clinical decision-making.
Combination treatments are studied because tumor suppression can involve several biological processes, including cell-cycle control, apoptosis, blood-vessel formation, immune recognition, and metastatic spread. Addressing more than one process may help investigators examine resistance from multiple angles. Researchers can then compare combined responses using tumor size, cellular activity, biomarkers, and metastatic potential while also considering effects on healthy tissue.